Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — H1 2024 Earnings Presentation

51 slides from Aspen Pharmacare's earnings presentation, Mar 5, 2024

  1. Slide 1: H1 2024 Interim Results

    H1 2024 INTERIM RESULTS 5 MARCH 2024

  2. Slide 2: Disclaimer

    Disclaimer • We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1

  3. Slide 3: Restatement of the group segmental analysis

    Restatement of the group segmental analysis The Group has revised and refined its reportable segments to reflect the updated operating model which supports the Group’s strategy for its Commercial Pharmaceuticals and Manufacturing businesses and aligns to the way in which the business is managed and

  4. Slide 4: Performance Overview

    PERFORMANCE OVERVIEW INTRODUCTION & HIGHLIGHTS

  5. Slide 5: Delivering on guidance and communicated strategic objectives

    Delivering on guidance and communicated strategic objectives H1 2024 highlights H2 2024 outlook • Commercial Pharma • Commercial Pharma » Achieved financial guidance » Momentum from H1 and acquisitive » Base business organic growth strong growth to positively impact H2 enough to absorb both China VB

  6. Slide 6: External and internal factors impacting earnings

    External and internal factors impacting earnings Commercial Pharma H1 2024 H2 2024 FY 2025 Q3 Q4 CHINA VBP^ No further material VBP^ impact on portfolio expected RUSSIA CIS H1 2023 represented last 6 months of higher COVID influenced sales Expected start date May 2024 SANDOZ CHINA Will offset China/

  7. Slide 7: H1 Performance & H2 Outlook

    H1 PERFORMANCE & H2 OUTLOOK GROUP REVENUE COMMERCIAL PHARMA GEOGRAPHY COMMERCIAL PHARMA SEGMENTS PRESCRIPTION OTC INJECTABLES MANUFACTURING HEPARIN

  8. Slide 8: Double-digit growth in Group reported revenue

    Double-digit growth in Group reported revenue % change R'million H1 2024 H1 2023 Reported CERⱡ Commercial Pharma 15 029 14 542 3% -3% Prescription 5 306 4 974 7% 1% OTC 4 893 4 451 10% 4% Injectables 4 830 5 117 -6% -12% Manufacturing 6 112 4 603 33% 17% Group revenue 21 141 19 145 10% 2% • 10% grow

  9. Slide 9: Strength in Commercial Pharma from geographical diversity

    Strength in Commercial Pharma from geographical diversity % change R'million H1 2024 H1 2023 Reported CERⱡ Africa Middle East 4 387 4 093 7% 7% Australasia 3 102 2 951 5% 0% Americas 3 098 2 428 28% 10% Europe CIS 2 363 2 442 -3% -12% Asia 2 079 2 628 -21% -25% Total Commercial Pharma 15 029 14 542

  10. Slide 10: Prescription, growth driver for H2 Commercial Pharma

    Prescription, growth driver for H2 Commercial Pharma % change R’million H1 2024 H1 2023 Reported CERⱡ Africa Middle East 1 994 1 964 2% 1% Australasia 1 400 1 392 1% -5% Americas 1 134 882 29% 10% Europe CIS 498 485 3% -9% Asia 280 251 12% 5% Prescription 5 306 4 974 7% 1% • Steady performance » Aus

  11. Slide 11: Strong OTC brands – Sustained growth in H2

    Strong OTC brands – Sustained growth in H2 % change R’million H1 2024 H1 2023 Reported CERⱡ Africa Middle East 1 833 1 734 6% 5% Australasia 1 227 1 125 9% 4% Europe CIS 943 826 14% 5% Americas 734 631 16% 0% Asia 156 135 16% 8% OTC 4 893 4 451 10% 4% • Good performance across regions » Middle East

  12. Slide 12: Pipeline to drive Injectables turnaround

    “Catching the falling sword” – Pipeline to drive Injectables turnaround % Change R’million H1 2024 H1 2023 Reported CERⱡ Asia 1 643 2 242 -27% -30% Americas 1 230 915 34% 17% Europe CIS 922 1 131 -18% -26% Africa Middle East 560 395 42% 43% Australasia 475 434 9% 4% Injectables 4 830 5 117 -6% -12%

  13. Slide 13: Sterile FDF revenues to boost Manufacturing growth

    Strong performance – Sterile FDF revenues to boost Manufacturing growth % Change R’million H1 2024 H1 2023 Reported CERⱡ API 2 404 2 034 18% 4% FDF 2 084 1 902 10% -2% Heparin 1 624 667 143% 111% Manufacturing 6 112 4 603 33% 17% • API growth important for profitability • FDF had COVID sales of R200

  14. Slide 14: Resolution of heparin working capital and commoditisation risks

    Resolution of heparin working capital and commoditisation risks Excess demand has changed Commoditisation de-risked Working Capital unwind The Heparin business will to excess supply convert to working capital • Long-term partnership • Ability to set fixed pricing • Opportunity to change and volumes

  15. Slide 15: Financial Review

    FINANCIAL REVIEW FINANCIAL HIGHLIGHTS GROSS MARGINS COMMERCIAL PHARMA BUSINESS SEGMENTS NORMALISED EBITDA FINANCE COSTS WORKING CAPITAL HEPARIN NET DEBT

  16. Slide 16: Normalised EBITDA ahead of H1 2023, exceeding guidance

    Normalised EBITDA^ ahead of H1 2023, exceeding guidance +2% CERⱡ -5% CERⱡ -5% CERⱡ +10% +2% +1% 21 141 643 688 19 145 5 194 586 566 680 5 083 H1 2023 H1 2024 H1 2023 H1 2024 H1 2023 H2 2023 H1 2024 H1 2023 H1 2024 Revenue Normalised EBITDA^ Normalised Net Financing^^ Normalised HEPS∑ (R'million) (R'

  17. Slide 17: Lower working capital investment drives strong operating cash flow

    Lower working capital investment drives strong operating cash flow +44% 88% 89% 27.3 55% 553 22.2 51% 58% 384 49% 1.9x 2.4x H1 2023 FY 2023 H1 2024 H1 2023 FY 2023 H1 2024 H1 2023 H1 2024 FY 2023 H1 2024 Operating cash conversion rate^ (%) Net working capital as % of Operating cash flow per share**

  18. Slide 18: Steady Commercial Pharma margins despite VBP pressure in China

    Steady Commercial Pharma margins despite VBP^ pressure in China Prescription 61.0% 60.9% 61.6% 58.1% 58.6% 58.8% OTC Favourable sales mix offsets Enhanced portfolio sales mix regulated price cuts in Australia ensured a positive trend H1 2023 H2 2023 H1 2024 H1 2023 H2 2023 H1 2024 Injectables 59.3%

  19. Slide 19: Consistent trends across Commercial Pharma and Manufacturing businesses

    Consistent trends across Commercial Pharma and Manufacturing businesses 59.5% 59.9% 59.8% 46.3% 46.1% 44.0% 16.5% 7.1% 5.3% H1 2023 H2 2023 H1 2024 H1 2023 H2 2023 H1 2024 H1 2023 H2 2023 H1 2024 Commercial Pharma Manufacturing Total Group Steady gross profit margin trend High heparin sales dilutes

  20. Slide 20: EBITDA exceeds reported H1 2023 by 2%

    EBITDA exceeds reported H1 2023 by 2% R'million H1 2024 % of revenue H1 2023 % of revenue % change % change CERⱡ Revenue 21 141 100.0% 19 150 100.0% 10% 2% Gross profit* 9 312 44.0% 8 966 46.8% 4% -3% Depreciation 669 3.2% 594 3.1% 13% 4% Operating expenses (4 998) 23.6% (4 621) 24.1% 8% 2% Net othe

  21. Slide 21: Lower foreign exchange losses offset higher interest costs

    Lower foreign exchange losses offset the impact of higher interest costs EM currencies against EUR: H1 2024 R’million H1 2024 FY 2023 H2 2023 H1 2023 Net interest paid 522 795 443 352 Effective interest rate for the period* 4.40% 3.21% 3.55% 2.83% 1.00 Foreign exchange losses 44 434 200 234 Normalis

  22. Slide 22: Sustainable reduction in working capital investment

    H1 2024 - Sustainable reduction in working capital investment -7% Operating cash conversion cycle +R88m 150% 117% 115% Cash 100% 89% 658 outflow 570 50% 50% 58% 22 210 0% H1 2022 H2 2022 H1 2023 H2 2023 H1 2024 939 R’million Operating cash conversion rate* Heparin: -R1,1bn 12 month moving average ca

  23. Slide 23: Heparin transitioning to a working capital light business model

    Heparin transitioning to a working capital light and sustainable future business model Heparin Inventory Investment -1.1 -3.0 -4.0 Heparin sales will spike in FY 2024 as the business transitions to the toll manufacturing model FY 2024 sales* expected to R’billion be around R3.6bn and 4.8 FY 2025 in

  24. Slide 24: Acquisitions and capex increase H1 2024 net debt levels

    Acquisitions and capex increase H1 2024 net debt levels 27 336 86 2 818* 6 327 22 184 3 814* 4 521 1 525 1 907 R’million 24 518 18 370 ^Includes R5.3bn Latam • Leverage ratio well portfolio acquisition funded below targeted from both operating and levels at 2.4x investment cash flows • FY 2024 proje

  25. Slide 25: ESG

    ESG ACCESS TO MEDICINE GENDER AND ENVIRONMENT

  26. Slide 26: Milestone achievements in providing access to medicine with purpose

    Our milestone achievements in providing access to medicine with purpose First FDA Generic MDR TB Over 1 million 225 million Covid Gavi vaccines Insulins ARV HIV/ AIDS doses for Africa patients reached in Africa Partnering with Opportunity to Novo to provide Manufactured manufacture access to over In

  27. Slide 27: Advancing gender equality and environmental performance

    Advancing gender equality and environmental performance for a sustainable tomorrow % of females in top management Gender diversity in the Group Water drawn (Megalitres) in the Group 1 693 35% 48% 37% 1 204 1 096 Reduction in water 1 039 1 061 17% withdrawn from the 2019 9 100 baseline employees 2019

  28. Slide 28: Renewable energy – Realising target to be off the grid

    Renewable energy Renewable energy- Realising target to be off the grid Manufacturing Various renewable energy projects are on track at our facilities SA facility progress • Power supply project that converts plastic waste to synthetic gas by pyrolysis is on track to come online in early CY 2025 • Gq

  29. Slide 29: Strategic Review

    STRATEGIC REVIEW COMMERCIAL PHARMA STRATEGY & GUIDANCE MANUFACTURING GUIDANCE EXISTING CONTRACTS & GAVI STERILE CAPACITY GUIDANCE H2 MANUFACTURING INFLECTION SUMMARY & PROSPECTS

  30. Slide 30: Strategy to de-risk the Commercial Pharma base

    Strategy to de-risk the Commercial Pharma base Focus is to drive organic growth and mitigate China VBP^ impact • Organic performance » H1 2024 growth was 3% » Excluding China/Russia CIS, organic growth of 11% • Sustainable VBP^ mitigation will de-risk base revenue » Acquiring Sandoz business in Chin

  31. Slide 31: Stronger growth for Commercial Pharma from H2

    Stronger growth for Commercial Pharma from H2 Acquisitions to impact H2 • Latam products and Lilly in SA » Effectively only 6 weeks of Latam Strong global pipelines in H1 • Organic momentum to continue to • Material FY 2025 product pipeline launches offset VBP^. Diprivan now also Attractive Emerging

  32. Slide 32: Strategic Review

    STRATEGIC REVIEW COMMERCIAL PHARMA STRATEGY & GUIDANCE MANUFACTURING GUIDANCE EXISTING CONTRACTS & GAVI STERILE CAPACITY GUIDANCE H2 MANUFACTURING INFLECTION SUMMARY & PROSPECTS

  33. Slide 33: Existing sterile manufacturing contracts and Gavi commitment

    Existing sterile manufacturing contracts and Gavi commitment Secured material contracted take-or-pay volume offtake Serum licensed products will also be a meaningful commitments contributor • Progress tangible, will impact in this year • Gavi delivers unequivocal support for African manufacturers »

  34. Slide 34: Increased contribution from existing sterile Manufacturing agreements

    Increased contribution from existing sterile Manufacturing agreements Anticipated Contribution On track for successful transfer of all projects (R’million) 4 500 4 000 4 000 • mRNA platform products transfer completed 3 500 3 000 3 000 2 500 2 000 1 500 Timing of Serum licensed products offtakes unc

  35. Slide 35: H2 an inflection point – big Manufacturing wheel turning

    H2 an inflection point – Revenue rolling – big Manufacturing wheel turning • Heparin unwind, a major achievement • For FDF steriles, H2 signals the beginning • Additional contracts on balance of capacity of contracted revenue flow under discussion/diligence • Rebound in profitable API Chemical busin

  36. Slide 36: Summary and Guidance

    Summary and Guidance Financial Performance Commercial Pharma • Reported normalised EBITDA for FY 2024 • H2 reported revenue anticipated to grow by R1bn over H2 2023 anticipated to grow mid-single digit » Performance underpinned by base organic growth and acquisitions • Targeted reduction of heparin

  37. Slide 37: Appendices

    APPENDICES APPENDIX 1 | ABRIDGED STATEMENT OF COMPREHENSIVE INCOME APPENDIX 2 | ABRIDGED STATEMENT OF NORMALISED COMPREHENSIVE INCOME APPENDIX 3 | RECONCILIATION OF REPORTED TO NORMALISED EBITDA APPENDIX 4 | RECONCILIATION OF NHEPS APPENDIX 5 | NORMALISED HEADLINE EARNINGS BRIDGE APPENDIX 6 | CURREN

  38. Slide 38: Abridged statement of comprehensive income

    Abridged statement of comprehensive income R’million H1 2024 H1 2023 % change FY 2023 Net revenue 21 141 19 150 10% 40 709 Cost of sales (11 829) (10 184) (21 775) Gross profit 9 312 8 966 4% 18 934 Gross profit margin 44.0% 46.8% 46.5% Operating expenses (4 998) (4 621) (9 426) Net other operating

  39. Slide 39: Abridged statement of normalised comprehensive income

    Abridged statement of normalised comprehensive income H1 2023 % change R’million H1 2024 H1 2023 % change (CERⱡ) (CERⱡ) FY 2023 Net revenue 21 141 19 150 10% 20 685 2% 40 709 Cost of sales (11 829) (10 184) 16% (11 116) 6% (21 775) Gross profit 9 312 8 966 4% 9 569 -3% 18 934 Gross profit margin 44.

  40. Slide 40: Reconciliation of reported to normalised EBITDA

    Reconciliation of reported to normalised EBITDA H1 2023 R’million H1 2024 H1 2023 % change (CERⱡ) % change FY 2023 Net revenue 21 141 19 150 10% 20 685 2% 40 709 Cost of sales (11 829) (10 184) (11 116) (21 775) Gross profit 9 312 8 966 4% 9 569 -3% 18 934 Operating expenses (4 998) (4 621) (4 920)

  41. Slide 41: Reconciliation of NHEPS

    Reconciliation of NHEPS H1 2023 % change Cents H1 2024 H1 2023 % change (CERⱡ) (CERⱡ) FY 2023 Basic earnings per share (EPS) 520.8 602.0 -13% 635.6 -18% 1 176.9 Impairment of property, plant and equipment 0.9 - - 0.7 Impairment of intangible assets 98.9 59.3 68.2 292.0 Reversal of impairment of inta

  42. Slide 42: Normalised headline earnings bridge

    Lower forex losses in H1 2024 aids normalised earnings growth +1% 192 172 3 058 3 019 111 92 R’million NHEPS = 688 cents H1 2023 Normalised EBITDA~ FX Impact Net interest Other^ H1 2024 ⱡ CER removes the currency effect on performance. The CER % change is based on H1 2023 figures that have been rest

  43. Slide 43: Weaker ZAR in H1 2024 lifts reported results

    Weaker ZAR in H1 2024 vs H1 2023 lifts reported results H1 2024 H1 2023 Normalised Normalised H1 2024 H1 2023 Currency contribution Revenue EBITDA Revenue EBITDA average rate average rate % change EUR 31% 12% 27% 7% 20.22 17.57 15% ZAR 15% 4% 16% 11% AUD 15% 20% 16% 26% 12.20 11.61 5% CNY 6% 10% 9%

  44. Slide 44: Tax rates remain within guided range

    Tax rates remain within guided range 20.4% 20.2% 20.2% 17.6% 17.0% 16.4% FY 2022 FY 2023 H1 2024 Group effective tax rate Group normalised effective tax rate • Normalised effective tax rate remained stable and within the guided range of 16% to 18% for FY 2024 44 APPENDIX 7 | EFFECTIVE TAX RATES

  45. Slide 45: Improved H1 2024 operating cash conversion rate of 89%

    Improved H1 2024 operating cash conversion rate of 89% R’million H1 2024 H1 2023 % change FY 2023 Cash operating profit 4 128 5 312 -22% 11 300 Changes in working capital (88) (2 168) 96% (3 358) Cash generated from operations 4 040 3 144 28% 7 942 Net finance costs paid (692) (500) 38% (808) Tax pa

  46. Slide 46: Sterile capex expansion project spend increased

    Sterile capex expansion project spend increased to meet customer and market related requirements PPE Capex ˠ in R’million 2 700 PPE Capex ˠ • The Sterile capacity expansion project in South Africa is progressing to plan with completion now expected in Q1 of CY 2 230 1 100 2025. Modifications to meet

  47. Slide 47: Reconciliation of normalised to reported net financing costs

    Reconciliation of normalised to reported net financing costs R’million H1 2024 FY 2023 H2 2023 H1 2023 Net interest paid 522 795 443 352 Effective interest rate for the period* 4.40% 3.21% 3.55% 2.83% Foreign exchange losses 44 434 200 234 Normalised net financing costs^^ 566 1 229 643 586 Debt rais

  48. Slide 48: Latam portfolio acquisition fully paid for in H1 2024

    Latam portfolio acquisition fully paid for in H1 2024 from operating and investment cash flows R'million H1 2024 Intangible assets acquired (5 292) Funded by cash flows from operating activities 2 063 Receivables forgone 939 Liabilities and provisions raised on acquisition 1 124 Cash outflow on acqu

  49. Slide 49: Refreshed Capital Allocation Framework supporting growth strategy

    Refreshed Capital Allocation Framework supporting growth strategy Subject to internal leverage cap of 3x 1 PPE capex and IP development 2 Acquisitions & disposals 3 Dividends paid 4 Larger acquisitions and disposals* R1 907 million R1 035 million R1 525 million R 5 292 million Ensure business Portfo

  50. Slide 50: Comparison of new vs old Commercial Pharma segments

    Comparison of new vs old Commercial Pharma segments H1 2023 % Change R’million H1 2024 H1 2023 % Change (CERⱡ) (CERⱡ) OLD SEGMENTATION Sterile brands 4 430 5 192 -15% 5 583 -21% Regional Brands 10 599 9 355 13% 9 876 7% Total Commercial Pharma 15 029 14 547 3% 15 459 -3% NEW SEGMENTATION Prescriptio

  51. Slide 51: Comparison of new vs old Manufacturing segments

    Comparison of new vs old Manufacturing segments H1 2023 % change R’million H1 2024 H1 2023 % Change (CERⱡ) (CERⱡ) OLD SEGMENTATION API 2 404 2 034 18% 2 322 4% Heparin 2 148 1 107 94% 1 275 68% FDF Other 833 809 3% 921 -10% FDF Steriles 726 653 11% 708 3% Manufacturing total 6 112 4 603 33% 5 226 17

Aspen Pharmacare Holdings — H1 2024 Earnings Presentation on 6ix